Paratek Pharmaceuticals Announces Positive Efficacy Data for NUZYRA® as Post-Exposure Prophylaxis of Inhalational Anthrax, Triggering Additional Procurement under BARDA Project BioShield Contract
March 05, 2024 06:45 ET
|
Paratek Pharmaceuticals, Inc.
Paratek Announces Positive Efficacy Data for NUZYRA®, Triggering Additional Procurement under BARDA Project BioShield Contract
Global Medical Foods Market Analysis Report 2024-2030: Shifting Trend Toward Disease-specific Formulas and Growing Demand for Neonatal and Preterm Enteral Feeding
March 05, 2024 04:13 ET
|
Research and Markets
Dublin, March 05, 2024 (GLOBE NEWSWIRE) -- The "Global Medical Foods Market Size, Share & Trends Analysis Report by Route of Administration, Product (Powder, Pills, Liquid, Other), Application,...
Global, Oncolytic Virus Therapy Research Report 2024: Market to Reach $53.06 Billion by 2028, Driven by Strategic Partnerships and Rising Awareness
March 04, 2024 11:02 ET
|
Research and Markets
Dublin, March 04, 2024 (GLOBE NEWSWIRE) -- The "Oncolytic Virus Therapy Market - Global Industry Size, Share, Trends, Opportunity, & Forecast 2018-2028" report has been added to ...
atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01
March 04, 2024 08:00 ET
|
atai Life Sciences
The Phase 1b trial of VLS-01 investigates the pharmacokinetics, pharmacodynamics, safety and tolerability of atai’s proprietary, optimized oral transmucosal formulation of DMTVLS-01 is being developed...
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
February 29, 2024 08:00 ET
|
Phathom Pharmaceuticals
Phathom Pharmaceuticals to host a conference call on Thursday, March 7, 2024, at 8:30 a.m. ET to report Q4 and full year 2023 financial results.
GH Research Reports Full Year 2023 Financial Results and Provides Business Updates
February 29, 2024 07:00 ET
|
GH Research PLC
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024Phase 2a clinical trial of GH001 in postpartum...
Nicotine Replacement Therapy Market Insights, Competitive Landscape, and Market Forecast to 2030
February 28, 2024 12:18 ET
|
Research and Markets
Dublin, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The "Nicotine Replacement Therapy - Market Insights, Competitive Landscape, and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's...
Growth Opportunities and Business Models Driving Sustainability in Pharmaceuticals Industry with Focus on Case Studies for Johnson & Johnson, Astra Zeneca, Pfizer, Piramal Pharma Solutions, and Amcor
February 26, 2024 11:16 ET
|
Research and Markets
Dublin, Feb. 26, 2024 (GLOBE NEWSWIRE) -- The "Growth Opportunities and Business Models Driving Sustainability in Pharmaceuticals Industry" report has been added to ResearchAndMarkets.com's...
Global L-Carnitine Market Size is Estimated to Reach USD 267.60 million by 2030, Growing at a CAGR of 4.7%: Straits Research
February 26, 2024 10:05 ET
|
Straits Research
New York, United States, Feb. 26, 2024 (GLOBE NEWSWIRE) -- L-carnitine is an amino acid that aids in fat metabolism and is used as a supplement in patients with low energy levels. Red meat, salmon,...
Uncle Bud's Health & Wellness Experiencing Powerful Growth One Month Following Acquisition by Pressure BioSciences, Inc.
February 26, 2024 09:06 ET
|
Pressure BioSciences, Inc.
Uncle Bud's Reports Early Synergies and Measurable Performance Metrics in First Month Since PBIO Acquisition